URGN Q2 2017 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$918M

Q2 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$6M

Net Income

-$6M

EPS (Diluted)

$-0.67

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$79M

Total Liabilities

$5M

Stockholders' Equity

$74M

Cash & Equivalents

$77M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$6M	-$3M	-75.3%
Net Income	-$6M	-$3M	-86.9%